Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (SGNTUC-019).
Authors
Evan Y. Yu
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
Evan Y. Yu , Fan Jin , Jorge Ramos , Qianwen Tan , Matt D. Galsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04579380
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS587)
DOI
10.1200/JCO.2023.41.6_suppl.TPS587
Abstract #
TPS587
Poster Bd #
P10
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
SGNTUC-019: Phase II basket study of tucatinib (TUC) and trastuzumab (Tras) in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (trial in progress).
First Author: Evan Y. Yu
Poster
2022 ASCO Genitourinary Cancers Symposium
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress).
First Author: Matt D. Galsky
Poster
2021 ASCO Annual Meeting
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
First Author: Tom Stinchcombe
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop